In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

the stock is currently trading near its 52-week low and appears undervalued based on their proprietary Fair Value model. This comprehensive analysis examines Regeneron's current position ...

But what about the other end of the spectrum? Let's take a quick look at the two worst performers on the Nasdaq-100 in May 2025.

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high estimate of $1081.00, and a low estimate of $547.00. A 9.11% drop is evident in ...

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Regeneron? Access our full analysis report here ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer consumer DNA testing services.

This comprehensive analysis examines Regeneron’s current ... could justify approximately $400-425 per share of Regeneron’s stock value on its own. If Regeneron successfully expands Dupixent ...

This comprehensive analysis examines Regeneron’s current position ... Analysts project that Dupixent could justify approximately $400-425 per share of Regeneron’s stock value on its own. If Regeneron ...